Literature DB >> 1287201

Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

M Davidian1, A R Gallant.   

Abstract

The seminonparametric (SNP) method, popular in the econometrics literature, is proposed for use in population pharmacokinetic analysis. For data that can be described by the nonlinear mixed effects model, the method produces smooth nonparametric estimates of the entire random effects density and simultaneous estimates of fixed effects by maximum likelihood. A graphical model-building strategy based on the SNP method is described. The methods are illustrated by a population analysis of plasma levels in 136 patients undergoing oral quinidine therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287201     DOI: 10.1007/bf01061470

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  14 in total

1.  A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.

Authors:  P O Maitre; M Bührer; D Thomson; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

2.  Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine.

Authors:  A Mallet; F Mentré; J L Steimer; F Lokiec
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

3.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  Population pharmacokinetics of quinidine.

Authors:  K Fattinger; S Vozeh; H R Ha; M Borner; F Follath
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

5.  Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

6.  Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.

Authors:  J L Steimer; A Mallet; J L Golmard; J F Boisvieux
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

7.  Population pharmacokinetic data and parameter estimation based on their first two statistical moments.

Authors:  S L Beal
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

Review 8.  Estimating population kinetics.

Authors:  S L Beal; L B Sheiner
Journal:  Crit Rev Biomed Eng       Date:  1982

9.  Computer-assisted drug assay interpretation based on Bayesian estimation of individual pharmacokinetics: application to lidocaine.

Authors:  S Vozeh; R Hillman; M Wandell; T Ludden; L Sheiner
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

10.  Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models.

Authors:  M S Driscoll; T M Ludden; D T Casto; L C Littlefield
Journal:  J Pharmacokinet Biopharm       Date:  1989-04
View more
  24 in total

Review 1.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

2.  A new approach to modeling covariate effects and individualization in population pharmacokinetics-pharmacodynamics.

Authors:  Tze Leung Lai; Mei-Chiung Shih; Samuel P Wong
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-10       Impact factor: 2.745

3.  Semiparametric distributions with estimated shape parameters.

Authors:  Klas J F Petersson; Eva Hanze; Radojka M Savic; Mats O Karlsson
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

4.  Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam.

Authors:  M Hossain; E Wright; R Baweja; T Ludden; R Miller
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

5.  A use of Monte Carlo integration for population pharmacokinetics with multivariate population distribution.

Authors:  A Yafune; M Takebe; H Ogata
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

6.  Bayesian individualization via sampling-based methods.

Authors:  J Wakefield
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

7.  Bayesian nonparametric population models: formulation and comparison with likelihood approaches.

Authors:  J Wakefield; S Walker
Journal:  J Pharmacokinet Biopharm       Date:  1997-04

8.  Estimation of population pharmacokinetics using the Gibbs sampler.

Authors:  N G Best; K K Tan; W R Gilks; D J Spiegelhalter
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

9.  Do we need full compliance data for population pharmacokinetic analysis?

Authors:  P Girard; L B Sheiner; H Kastrissios; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1996-06

10.  Population pharmacokinetic modeling: the importance of informative graphics.

Authors:  E I Ette; T M Ludden
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.